Key result
MEGF10 overexpression reduces myoblast fusion ~91% and its loss blunts hypertrophic response to muscle overload.
Why the study?
Biallelic mutations in MEGF10 cause EMARDD, a severe recessive myopathy linked to reduced satellite cells, but the role of MEGF10 in satellite cells required better understanding.
MEGF10 promotes satellite cell adhesion and survival and prevents premature fusion, which may explain its role in the severe recessive myopathy EMARDD.
Answers are grounded in this paper and cite their sources.
MEGF10 regulates myoblast fusion and overload hypertrophy; hypothesis-generating for EMARDD pathogenesis with no immediate clinical implications.
Biallelic mutations in multiple EGF domain protein 10 ( MEGF10 ) gene cause EMARDD (early myopathy, areflexia, respiratory distress and dysphagia) in humans, a severe recessive myopathy, associated with reduced numbers of PAX7 positive satellite cells. To better understand the role of MEGF10 in satellite cells, we overexpressed human MEGF10 in mouse H-2k b -tsA58 myoblasts and found that it inhibited fusion. Addition of purified extracellular domains of human MEGF10, with (ECD) or without (EGF) the N-terminal EMI domain to H-2k b -tsA58 myoblasts, showed that the ECD was more effective at reducing myoblast adhesion and fusion by day 7 of differentiation, yet promoted adhesion of myoblasts to non-adhesive surfaces, highlighting the importance of the EMI domain in these behaviours. We additionally tested the role of Megf10 in vivo using transgenic mice with reduced ( Megf10 +/− ) or no ( Megf10 −/− ) Megf10. We found that the extensor digitorum longus muscle had fewer anti-Pax7 stained cell nuclei and was less able to undergo hypertrophy in response to muscle overload concomitant with a lower level of satellite cell activation. Taken together, our data suggest that MEGF10 may promote satellite cell adhesion and survival and prevent premature fusion helping to explain its role in EMARDD.
No takes yet. Share an insight, caveat, or question.
Richardson et al. (2025) studied EMARDD / Skeletal muscle myopathy. MEGF10 overexpression and Megf10 knockout vs. Wild-type or control cells/mice was evaluated on Myoblast fusion index (p=<0.0001). Overexpression of MEGF10 in myoblasts reduced the fusion index to 7.5% compared to 80% in controls, and loss of Megf10 in vivo blunted the hypertrophic response to muscle overload.
Synapse has enriched 10 related papers. Consider them for comparative context: